{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-270979","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.666643+00:00","generated_at":"2026-06-22T23:58:10.137092+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Agios sells TIBSOVO royalty rights to Sagard for $131.8M upfront","bullets":["Upfront cash payment of $131.8M for 5% royalty on U.S. net sales of TIBSOVO (ivosidenib).","Agios retains $200M milestone for vorasidenib and 15% royalties on its U.S. net sales.","Deal provides non-dilutive capital to fund PYRUKYND launch and ongoing pipeline programs.","Transaction closed on October 27, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-270979","json":"https://secwatch.observer/filing/0001193125-22-270979.json","markdown":"https://secwatch.observer/filing/0001193125-22-270979.md","text":"https://secwatch.observer/filing/0001193125-22-270979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522270979/0001193125-22-270979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522270979/d409394d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:58:10.137092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4d9103d8d5b48c44afbfaab2b63412c3c70516a","claim":"AGIOS PHARMACEUTICALS, INC. entered into Purchase and Sale Agreement with Sagard Healthcare Royalty Partners, LP, Sagard Healthcare Partners Co-Invest Designated Activity Company valued at $131,783,241 (effective 2022-10-27).","evidence_excerpt":"On October 27, 2022, Agios Pharmaceuticals, Inc. (the “Company”) entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempt limited partnership, and Sagard Healthcare Partners Co-Invest Designated Activity Company, a company incorporated in Ireland, as purchasers (together, the “Purchasers”), and Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempt limited partnership, as the Purchaser’s representative.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522270979/0001193125-22-270979-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Sagard Healthcare Royalty Partners, LP, Sagard Healthcare Partners Co-Invest Designated Activity Company"},{"label":"Value","value":"$131,783,241"},{"label":"Effective","value":"2022-10-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}